Research that reveals a better understanding of neurological systems, and the diseases that affect them, could translate into cures that improve millions of lives. BioLegend offers a wide-ranging portfolio of products, providing solutions for your neuroscience experiments, including antibodies, immunoassay solutions, recombinant proteins, magnetic cell separation, and single-cell proteogenomics reagents. Our reagents were built in collaboration with preeminent leaders in the field, like The Michael J. Fox Foundation (see the Product Highlights tab below), signifying our commitment to partner with your teams to seek out new discoveries, bringing our customers new choices and comprehensive solutions for studying neurological disorders.

 

Contact your local technical representative to collaborate, partner, and discover new opportunities.

Neurodegeneration


Neurodegenerative diseases result from the loss of neurons in the nervous system, which can have debilitating effects like dementia, memory loss, and ataxia. Treatment for these diseases are limited, raising the need to gain a better understanding of their mechanisms and origins. Utilize reliable protein- and modification-specific antibodies, recombinant proteins, assay kits, and reagents to study protein aggregation and cellular processes involved in neurodegeneration. Learn more about each of the subset and the reagents we offer for them below.

Protein Aggregation

Neurodegeneration is a complex biological process that is often defined by the presence of protein aggregates. Protein aggregation is a result of misfolded proteins forming fibrils, inclusion bodies, and other large proteinaceous inclusions such as plaques. Many neurodegenerative disorders are associated with aggregation of key target proteins including Amyloid-β (Aβ) and Tau in Alzheimer's disease, and α-Synuclein in Parkinson's disease. Protein aggregates exert their toxic function by disrupting normal cellular and synaptic functions ultimately resulting in cell death. We provide a large assortment of antibodies, kits, and recombinant proteins to study the function of these targets in a neurological setting.


Neuroinflammation




BioLegend’s immunology portfolio provides numerous resources to complement neuroinflammation research, which involves signaling proteins, receptors, and cells. Our reagents can phenotype a variety of cell types, including resident glial cells in the central nervous system, non-glial resident myeloid cells, and peripheral leukocytes.
 

View our Neuroinflammation Webpage.

View our Neuroinflammation Brochure.

Autophagy




Autophagy is a process that degrades and removes dysfunctional proteins, damaged organelles, and intracellular pathogens by delivering cytoplasmic material to the lysosome. Dysregulation of autophagy can have fatal consequences for cells, which is why it has been linked to diseases like cancer, neurodegeneration, and pathogenic infections.

 

View our Autophagy Webpage.

View Bio-Bit on Aggrephagy and Protein Aggregate Degradation.

 



Synaptic Function




The neuron relays electrical and chemical signals to other neurons at junctions known as the neural synapse. With an estimated 100 billion neurons in the mammalian CNS, it is vital to understand the hundreds of proteins that coordinate the basis for higher nervous system functions, such as cognition, memory, and movement.

 

View all Synapse Products.

View our Synaptic Function Webpage.

 

View Bio-Bits:

Neurotransmitter Receptor Sorting and Trafficking in Neurons

Novel Antibodies to Study Synaptic Biology

The Role of BMP-4 in Synapse Elimination

Synaptic Biology and Reagent Price Reduction

Synaptic Vesicle Exocytosis

Epigenetics



 

Epigenetics describes heritable modifications to DNA chromatin modeling that can hide or reveal function without altering the genetic code itself. In neuroscience, these modifications are not passed down to progeny (since neurons do not divide). However, more and more studies are identifying how epigenetics can help neural cells with information storage and circuit regulation. Failure or alteration of epigenetic systems in these cells may lead to neurodegenerative disease.

 

 

View our epigenetics products.

View our Bio-Bit on Histones and Regulation of Transcription through Epigenetic Modification.

Astrocytes



Astrocytes are the most common glial cell type in the brain, and perform many functions such as neurotransmitter uptake and release, modulation of synaptic transmission, and nervous system repair. Astrocytes have been implicated in the pathogenesis of neuropsychiatric and neurodevelopmental disorders. Use our Astrocyte Webpage to learn about the role of astrocytes in ASD, ALS, and Rett syndrome and the reagents we provide to study them.

 

Microglia



Microglia are the resident immune cells of the central nervous system. They have many normal physiological functions such as synaptic remodeling and maturation. Dysregulation of microglial function has been associated with many neurological disorders including Alzheimer’s (AD) and Parkinson’s disease (PD). Our Microglia Webpage provides background information on microglia and their role in AD, PD and CNS injury.

 


Oligodendrocytes



 

Oligodendrocytes are known as the myelinating cells of the central nervous system responsible for producing myelin to insulate axons. Damage to myelin sheathes and oligodendrocytes is a key feature in multiple sclerosis. Browse through a variety of reagents with our Oligodendrocyte Webpage to better phenotype them.

 

Neurons



 

Neurons have highly compartmentalized structures that are generally classified into soma, axon, dendrite, axonal terminal, and synapse. We offer directly-conjugated antibodies, available in multiple sizes and against markers that are expressed in each structural unit of a neuron, and allow their identification using applications such as IHC and ICC. Learn more with our Neuron Webpage.

We partner with our customers and collaborators to create unique products that drive innovation. Learn more about some of the featured neuroscience products and how they can advance your research.

 

A Strong Partnership with The Michael J. Fox Foundation

The Michael J. Fox Foundation (MJFF) is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. As BioLegend shares similar aspirations of pushing from Research to Cure, we collaborate with the MJFF to create unique products, like our highly specific LEGEND MAX™ α-synuclein ELISA Kit (A), which shows assay recovery and sensitivity, and useful  clones including:

  • Anti-Parkin (clone 5C3/Parkin), tested by western blotting on human and rat brain lysates (B).
  • Anti-LRRK2 (clone MC.028.83.76.242), QC-tested in IHC-P assays (C).
  • Anti-Rab8 (clone A18073A), an affordable antibody clone useful in WB and ICC assays (D).

Michael J. Fox Foundation
Learn more about MJFF.


 


 

Aggregate-Specific Clones

 

Aggregate-Specific ClonesHaving reagents that can differentiate between aggregated and non-aggregated forms of proteins is vital in researching neuropathies. To this end, we’ve created a number of in-house clones that recognize aggregated α-Synuclein (clones A17183A, A17183B, and A17183G). Each clone has been validated for FFPE Parkinson’s disease brain tissue in IHC and demonstrates  no cross-reactivity to native forms of α-Synuclein, β- and γ-Synucleins or β-Amyloid (Ab 1-42).

 

For aggregated β-Amyloid, we have clones A17171C and 3A1, which demonstrate no cross-reactivity with full-length APP. Clone A17171C detects high molecular weight aggregates with a higher sensitivity compared to clone 3A1. Our in-house testing on these clones confirmed they detect Aβ fragments and a preference for aggregated Aβ.


Proteogenomics and TotalSeq™
 

Proteogenomics and TotalSeq™


Proteogenomics allows researchers to get deeper insight into the multi-tiered complexity of individual cells by simultaneously capturing a potentially limitless number of protein markers and unbiased transcriptome analysis using existing single-cell sequencing approaches. To this end, BioLegend provides TotalSeq™ oligonucleotide-labeled antibodies to characterize and phenotype cells of interest.

 

View all neuroscience TotalSeq™ antibodies

View our TotalSeq™ Webpage.

Sternberger Monoclonals
 

Sternberger Monoclonals


The Sternberger (SMI®) antibodies were developed by Dr. Ludwig Sternberger. This product line offers a variety of highly specific neuroscience cell marker antibodies that have become the gold standard in IHC studies for markers such as neurofilaments, myelin basic protein, GFAP, MAP2, and others.

 

View our Sternberger Antibodies.

View our Bio-Bit on SMI® Antibodies.


Antibodies for Drosophila
 


 

Many genes associated with human diseases are conserved in Drosophila melanogaster, an attractive model organism for neuroscience. Flies have short life cycles, are easy to maintain, and can produce large sample sizes. BioLegend is expanding its collection of antibodies validated for Drosophila research to provide more options for more scientists.

 

View all Drosophila Antibodies.


 

Consistent Innovation

As new markers and methods are discovered for the neuroscience research area, we strive to place innovative products in our partners’ hands. Recently, P2RY12 has gained attention as a novel microglia marker. To help researchers, we provide Mouse MojoSort™ P2RY12 Selection Kits and a diverse array of directly conjugated anti-P2RY12 antibodies. We also provide guidance on technique with useful protocols for whole mouse brain processing or astrocyte isolation and culturing. As researchers find new avenues to pursue, we want to ensure they are empowered with the right applications and tools to conduct their work.

 

Partner with us to find your research solution.

Looking for inspiration or wanting to learn more about neuroscience? Discover our website’s latest news and video resources. You can also learn more about our product lines and request helpful posters, brochures, and information sheets from our literature webpage.

 

Videos | News

Videos


 

Sponsored Webinars


News and Events


NIH and Michael J. Fox Foundation Announce Partnering Program for Parkinson’s Disease Research

The NIH and the Michael J. Fox Foundation have announced a partnership program along with biopharmaceutical and life science companies that will focus on disease markers for Parkinson’s Disease progression as part of the NIH Accelerating Medicines Partnership (AMP). BioLegend is proud to be a participant and sponsor for the MJFF-led Parkinson’s Progression Markers Initiative (PPMI), which will contribute data and samples for the program. Our LEGEND MAX™ Human α-Synuclein ELISA kit has been used extensively in PPMI’s multi-centered studies for the measurement of α-Synuclein in biological samples. 

Read the NIH press release, the MJFF press release, and learn more about the MJFF Parkinson’s Progression Markers Initiative.

BioLegend Synaptic Biology Antibody Price Reduction

BioLegend is continually striving to provide top quality reagents to support neuroscience research. Our extensive catalog contains a wide selection of antibodies that recognize targets relevant in Synaptic Biology. We are committed to offering these products at a great value to our customers in an effort to accelerate research and discovery in this area. To this end, we are pleased to announce a permanent price reduction of up to 40% on over 70 targets in this category. Take advantage of this offering and submit a product review from this selection of antibodies to receive a $25 Amazon gift card.

Learn More

SelectScience articles

Editorial Article: Microglia Prune Synapses and Shape Neural Circuits During Development

Learn how Dr. Dorothy Schafer utilizes reliable antibodies to study how microglia help in sculpting neuronal circuits during development. Read full story…


 

Editorial Article: Impaired Protein Homeostasis in Neurodegenerative Diseases

Learn how selective antibodies help decipher an impaired autophagy pathway in spino-bulbar muscular atrophy. Read full story…


 

Editorial Article: 3D Bioengineered Brains – a New Approach to Personalized Cancer Therapy

Learn how tissue bioengineer Dr. Tang-Schomer is working to make personalized medicine a reality for brain cancer patients. Read full story…


 

Editorial Article: Using Transgenic Mouse Models to Improve Understanding of Epilepsy and Advance the Search for Effective Therapeutics

Learn how molecular biologist Dr. Antonella Pirone is investigating synaptic organization and helping to find and develop drug candidates to treat epileptic disorders. Read full story…


 

Editorial Article: Neurological Regenerative Medicine – Unlocking the Potential of Stem Cells in the Olfactory System

Learn how stem cell biologist Dr. Barbara Murdoch’s research into our sense of smell could help develop new neurodegenerative disease therapies. Read full story…


Product Authors Journal Year Vol/Page Pubmed
Purified anti-0N Tau Ercan E, et al. Mol Neurodegener. 2017 10.1186/s13024-017-0229-1 Link
Purified anti-0N Tau Qu X, et al. J Cell Biol 2017 216:3161 Link
Purified anti-2N Tau Ercan E, et al. Mol Neurodegener. 2017 10.1186/s13024-017-0229-1 Link
Purified anti-AICD Tampellini D, et al. J Neurosci 2011 31:15384-15390 Link
Purified anti-APP Sano O, et al. PLoS One 2016 11: 0155400 Link
Purified anti-APP Osborne C, et al. J Cell Sci 2018 131: Link
Purified anti-APP C-Terminal Fragment Corbett G, et al. Proc Natl Acad Sci U S A 2015 112: 8445 - 8450 Link
Purified anti-APP C-Terminal Fragment Jiang Y, et al. Proc Natl Acad Sci U S A 2010 107:1630-1635 Link
Purified anti-APP C-Terminal Fragment Paschkowsky S, et al. J Biol Chem 2016 291: 21903 - 21912. Link
Purified anti-APP C-Terminal Fragment Miranda AM, et al. Nat Commun 2018 9:291 Link
  • Page 1 of 148
ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login/Register
Forgot your password? Reset Password
Request an Account